慢性鼻窦炎生物靶向药物治疗的研究进展

Research progress in biologic targeted drug therapy for chronic sinusitis

慢性鼻窦炎(CRS)是一种鼻腔鼻窦的慢性炎症性疾病,根据其发病机制可分为1型、2型和3型炎症内在型。目前CRS的药物治疗及手术治疗方法均存在发生各种不良反应和并发症的风险,其中部分难治性鼻窦炎虽经适当的药物和手术治疗仍不能取得满意效果并极易复发,严重影响患者的生活质量。生物靶向药物的应用和发展为CRS的治疗提供了一种有效和安全的替代方案。本文着重介绍针对CRS三种炎症内在型的相关细胞因子(包括TNF-α、IL-4、IL-5、IL-13、IgE和IL-17等)的生物靶向药物治疗的研究进展。

Chronic sinusitis(CRS)is a chronic inflammatory disease of the nasal cavity and sinuses.Based on its pathogenesis,CRS can be divided into type 1,type 2,and type 3 inflammatory intrinsic type.At present,the drug therapy and surgical treatment of CRS have the risk of various adverse reactions and complications;among these cases of refractory sinusitis,some cannot achieve satisfactory results and are prone to recurrence despite appropriate drug and surgical treatment,thus seriously affecting the quality of life of patients.The application and development of biologic targeted drugs provide an effective and safe alternative to the treatment of CRS.This review focuses on the research progress of biologic targeted drug therapy targeting the cytokines associated with the three intrinsic types of CRS inflammation,including TNF-α,IL-4,IL-5,IL-13,IgE,and IL-17.